- Details
- (Length of Discussion: 10 min) Edward (Ted) Schaeffer, MD, Ph.D. and Alicia Morgans, MD share a dynamic discussion on the risk strategy that may be employed for high-risk prostate cancer patients including oligometastatic disease. They share observations such as an increase in patient volume in their clinics of men with rising PSAs, high grade and locally advanced disease. In discussing the best w...
|
- Details
- (Length of Discussion: 7 min) Stacy Loeb, MD, and Alicia Morgans, MD discuss conservative management, active surveillance, and management trends over time for low-risk prostate cancer in the Veterans Affairs Integrated Health Care System over the past decade. Biographies: Stacy Loeb, MD, is an Assistant Professor of Urology and Population Health at New York University (NYU), specializing in prosta...
|
- Details
- Sigrid Carlsson, MD talks with Alicia Morgans, MD about long-term outcomes of active surveillance for prostate cancer, a 17-year experience with active surveillance at the Memorial Sloan Kettering Cancer Center. A study which Carlsson was a co-author on and was presented at the most recent American Urological Association meeting (AUA2018). This was a retrospective analysis of all patients managed...
|
- Details
- (Length of Conversation: 10 min) Alex Kutikov, MD, FACS talks with Alicia Morgans, MD, MPH on the multidisciplinary management of genitourinary oncology and his experiences at Fox Chase Cancer Center. This discussion includes the importance of the collaborative care for the patient from the radiation oncologist, medical oncologist, and urologist and the nuances of this co-management with the numbe...
|
- Details
- (Length of Discussion: 12 min) Daniel George, MD talks with Charles Ryan, MD and discusses a number of recent studies Daniel and his colleagues at Duke University School of Medicine have been focused on related to race and abiraterone outcomes in prostate cancer patients and how this new information impacts clinical practice. Studies and Presentations Discussed in Discussion: Overall Survival Betw...
|
- Details
- Felix Feng, MD talks with Alicia Morgans, MD, MPH on identifying subsets of patients with prostate cancer that are most responsive to certain therapies so the physician can better individualize treatment options for patients. Topics they discuss include predictive biomarkers, hormone therapy, early initiation of hormone therapy for patients treated with surgery up front. In addition, they also dis...
|
- Details
- J Kellogg Parsons MD, talks with Alicia Morgans prior to his presentation of The Men’s Eating and Living (MEAL) Study (CALGB 70807 [Alliance]): A Randomized Clinical Trial of a Diet Intervention in Men on Active Surveillance for Prostate Cancer at the 113th Annual Scientific Meeting of the American Urological Association (AUA) . A much-anticipated presentation of work assessing the feasibility of...
|
- Details
- (Length of Presentation: 20 min) Jehonathan Pinthus presents the role of androgen deprivation therapy (ADT) in promoting cardiovascular disease (CVD) and focuses on two prospective studies, one of which is embedded in the other. The Role of Androgen Deprivation Therapy in Cardiovascular Disease – A Longitudinal Prostate Cancer Study (RADICAL PC1) is a prospective cohort study of men within one yea...
|
- Details
- (Length of Presentation: 16 min) Alicia Morgans, MD presents a Geriatric Assessment of Men with Prostate Cancer. She outlines the importance of geriatric considerations in prostate cancer and implementing it into the clinical management of patients. She details initial treatment decision making including staging the aging and estimation of remaining life expectancy. She also discusses consideratio...
|
- Details
- (Length of Discussion: 21 min) Tom Keane brings new concepts in androgen deprivation therapy (ADT) to light specifically discussing agonists versus antagonists, new androgen receptor-targeted drugs, including immunotherapy biomarkers, and genomic testing. He reviews the current state of the CRPC treatment and ADT options for use in advanced metastatic disease and concludes with a discussion on tre...
|
